Document Type : Original Article


1 Department of Internal Medicine, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

2 Clinical Research Development Unit, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran Department of Family Medicine, Ali-Ibn Abi-Talib Hospital, School of Medicine, Rafsanjan University of Medical

3 Clinical Research Development Unit, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Department of Family Medicine, Ali-Ibn Abi-Talib Hospital, School of Medicine, Rafsanjan University of Medical

4 Clinical Research Development Unit, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran


Renal involvement is one of the extra-articular manifestations of rheumatoid arthritis (RA). The current study aims to investigate renal function and its associated factors in RA patients. This cross-sectional study included 443 RA patients who were referred to Rafsanjan's only rheumatology clinic in 2021. Disease Activity Score 28 (DAS28) index was used to determine disease activity. Blood levels of creatinine, C-Reactive Protein test (CRP), Erythrocyte Sedimentation Rate (ESR), and urine analysis were also determined. Renal failure was classified based on Estimated Glomerular Filtration Rate (eGFR). SPSS.20 one-way ANOVA, Kruskal-Wallis test, the Mann-Whitney U test, and Chi-square were used to analyze the data. Patiens' mean age was 53.99 ± 12.34, and 85.8% (380 people) of the participants were female. Ther were 147 (33.2%) patients without renal failure, 260 (58.7%) with mild renal failure, and 36 (8.1%) with moderate/severe failure. Men had a 3.059 higher risk of renal failure than women (P = 0.001). The probability of developing renal failure in patients increased by 1.047 times with each year of age (P < 0.001). As a chronic disease, RA can directly or through the use of disease medications and other risk factors, adversely affect other organs of the body, including the kidney. The current study's findings revealed a high prevalence of mild renal failure in these patients.


Main Subjects

  1. Conforti A, Di Cola I, Pavlych V, Ruscitti P, Berardicurti O, Ursini F. et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev 2021; 20(2):102735. doi: 10.1016/j.autrev.2020.102735.
  2. .Kelly W, Harris EJ, Ruddy S, Sledge C. Textbook of rheumatology. 5th ed. Philadelphia: WB Saunders. 2012:107-15.
  3. Smolen JS, Aletaha D. The assessment of disease activity in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28(3 Suppl 59):S18-27.
  4. Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL. Sex and Management of Rheumatoid Arthritis. Clin Rev Allergy Immunol 2019; 56(3):333-45. doi: 10.1007/s12016-018-8672-5.
  5. Davatchi F: Pattern of rheumatic diseases in Asia-pacific and the tropics. In: Annual Scientific Meeting of American College of Rheumatology: 2005; 2005: 3-5
  6. Jamshidi AR, Tehrani Banihashemi A, Roknsharifi S, Akhlaghi M, Salimzadeh A, Davatchi F. Estimating the prevalence and disease characteristics of rheumatoid arthritis in Tehran: A WHO -ILAR COPCORD Study (from Iran COPCORD study, Urban Study stage 1). Med J Islam Repub Iran 2014; 28:93.
  7. Akhlaghi M, Askarishahi M, Sabzmakan L. Quality of life and Related Factors in Rheumatoid Arthritis Patients.  J Health Res Commun. 2016;2(3):1-11.
  8. Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 2002; 16(5):707-22. doi: 10.1053/berh.2002.0257
  9. Chaleshgar kordasiabi M, Akhlaghi M, Askarishahi M, Sabzmakan L, Abbasi shavazi M. Quality of life and Related Factors in Rheumatoid Arthritis Patients %J Journal of health research in community. 2016;2(3):1-11.
  10. Branimir A, Miroslav M. [Pathogenesis of rheumatoid arthritis]. Reumatizam 2014; 61(2):19-23
  11. Lin Y-J, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells 2020; 9(4):880. doi: 10.3390/cells9040880.
  12. Durán J, Massardo L, Llanos C, Iacobelli S, Burgos PI, Cisternas M. et al. The Prevalence of Rheumatoid Arthritis in Chile: A Nationwide Study Performed as Part of the National Health Survey. J Rheumatol 2020; 47(7):951-58. doi: 10.3899/jrheum.190396
  13. Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR. Kelley and Firestein's textbook of rheumatology: Elsevier Health Sciences; 2016.
  14. Yap HY, Tee SZ, Wong MM, Chow SK, Peh SC, Teow SY. Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development. Cells 2018; 7(10):161.doi: 10.3390/cells7100161.
  15. Saadat SH, Ramezani A, Ahmadi K. Sexual Self-Concept and General Health in Rheumatoid Arthritis Patients. Iran Red Crescent Med J 2015; 17(10):e19005. doi: 10.5812/ircmj.19005
  16. Fayed A, Shaker A, Hamza WM, Wadie M. Spectrum of glomerulonephritis in Egyptian patients with rheumatoid arthritis: A University Hospital experience. Saudi J Kidney Dis Transpl 2019; 30(4):803-11. doi: 10.4103/1319-2442.265455.
  17. Kapoor T, Bathon J. Renal Manifestations of Rheumatoid Arthritis. Rheum Dis Clin North Am 2018; 44(4):571-84. doi: 10.1016/j.rdc.2018.06.008.
  18. kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y. Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis. PLoS One 2016; 11(8):e0160225. doi: 10.1371/journal.pone.0160225
  19. Lousa I, Reis F, Beirão I, Alves R, Belo L, Santos-Silva A. New Potential Biomarkers for Chronic Kidney Disease Management-A Review of the Literature. Int J Mol Sci 2020; 22(1):43. doi: 10.3390/ijms22010043.
  20. Hickson LJ, Crowson CS, Gabriel SE, McCarthy JT, Matteson EL. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis 2014; 63(2):206-13. doi: 1053/j.ajkd.2013.08.010.
  21. Chiu HY, Huang HL, Li CH, Chen HA, Yeh CL, Chiu SH. et al. Increased Risk of Chronic Kidney Disease in Rheumatoid Arthritis Associated with Cardiovascular Complications - A National Population-Based Cohort Study. PLoS One 2015; 10(9):e0136508. doi: 10.1371/journal.pone.0136508.
  22. Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y. Chronic kidney disease, inflammation, and cardiovascular disease risk in rheumatoid arthritis. J Cardiol 2018; 71(3):277-83. doi: 10.1016/j.jjcc.2017.08.008.
  23. Icardi A, Araghi P, Ciabattoni M, Romano U, Lazzarini P, Bianchi G. [Kidney involvement in rheumatoid arthritis]. Reumatismo 2003; 55(2):76-85. doi: 10.4081/reumatismo.2003.76.
  24. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62(9):2569-81. doi: 10.1002/art.27584.
  25. Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J. Harrison's principles of internal medicine: McGraw-hill education New York; 2018.
  26. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J. et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68(6):954-60. doi: 10.1136/ard.2007.084459.
  27. Moorthy AV, Becker BN, Boehm FJ, Djamali A. Pathophysiology of Kidney Disease and Hypertension E-Book: Elsevier Health Sciences; 2017.
  28. Koseki Y, Terai C, Moriguchi M, Uesato M, Kamatani N. A prospective study of renal disease in patients with early rheumatoid arthritis. Ann Rheum Dis 2001; 60(4):327-31. doi: 10.1136/ard.60.4.327.
  29. Karie S, Gandjbakhch F, Janus N, Launay-Vacher V, Rozenberg S, Mai Ba CU. et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 2008; 47(3):350-4. doi: 10.1093/rheumatology/kem370.
  30. Sihvonen S, Korpela M, Mustonen J, Laippala P, Pasternack A. Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis. Nephron Clin Pract 2004; 96(4):c107-14. doi: 10.1159/000077372.
  31. Bouya S, Balouchi A, Rafiemanesh H, Hesaraki M. Prevalence of Chronic Kidney Disease in Iranian General Population: A Meta-Analysis and Systematic Review. Ther Apher Dial 2018; 22(6):594-99. doi: 10.1111/1744-9987.12716.
  32. Saisho K, Yoshikawa N, Sugata K, Hamada H, Tohma S. Prevalence of chronic kidney disease and administration of RA-related drugs in patients with RA: The NinJa 2012 study in Japan. Mod Rheumatol 2016; 26(3):331-5. doi: 10.3109/14397595.2015.1088620.
  33. Couderc M, Tatar Z, Pereira B, Tiple A, Gilson M, Fautrel B. et al. Prevalence of Renal Impairment in Patients With Rheumatoid Arthritis: Results From a Cross-Sectional Multicenter Study. Arthritis Care Res (Hoboken) 2016; 68(5):638-44. doi: 10.1002/acr.22713.
  34. Mori S, Yoshitama T, Hirakata N, Ueki Y. Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: a cross-sectional study in community hospitals. Clin Rheumatol 2017; 36(12):2673-82. doi: 10.1007/s10067-017-3804-5.
  35. Helin HJ, Korpela MM, Mustonen JT, Pasternack AI. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 1995; 38(2):242-7. doi: 10.1002/art.1780380213.
  36. Nakano M, Ueno M, Nishi S, Shimada H, Hasegawa H, Watanabe T. et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 1998; 50(3):154-60. Journal Article.
  37. Harrison M. Erythrocyte sedimentation rate and C-reactive protein. Aust Prescr 2015; 38(3):93-4. doi: 10.18773/austprescr.2015.034.
  38. Berntson L, Nordal E, Fasth A, Aalto K, Herlin T, Nielsen S. et al. Anti-type II collagen antibodies, anti-CCP, IgA RF and IgM RF are associated with joint damage, assessed eight years after onset of juvenile idiopathic arthritis (JIA). Pediatr Rheumatol Online J 2014; 12:22. doi: 10.1186/1546-0096-12-22.
  39. Stojan G, Fang H, Magder L, Petri M. Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity. Lupus 2013; 22(8):827-34. doi: 10.1177/0961203313492578.
  40. Wu CL, Chang CC, Kor CT, Yang TH, Chiu PF, Tarng DC. et al. Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis. Clin J Am Soc Nephrol 2018; 13(5):702-09. doi: 10.2215/cjn.11781017.
  41. Nazir AM, Koganti B, Gupta K, Memon MS, Aslam Zahid MB, Shantha Kumar V. et al. Evaluating the Use of Hydroxychloroquine in Treating Patients With Rheumatoid Arthritis. Cureus 2021; 13(11):e19308. doi: 10.7759/cureus.19308.
  42. Onishi A, Akashi K, Yamamoto W, Ebina K, Murata K, Hara R. et al. The Association of Disease Activity and Estimated GFR in Patients With Rheumatoid Arthritis: Findings From the ANSWER Study. Am J Kidney Dis 2021; 78(5):761-64. doi: 10.1053/j.ajkd.2021.02.338.
  43. Chebotareva NV, Gulyaev SV, Androsova TV, Popova EN, Gurova DV, Novikov PI. et al. [Clinicopatological variants and risk factors for chronic kidney disease in rheumatoid arthritis]. Ter Arkh 2020; 92(5):55-60. doi: 10.26442/00403660.2020.05.000604.
  44. Anders HJ, Vielhauer V. Renal co-morbidity in patients with rheumatic diseases. Arthritis Res Ther 2011; 13(3):222. doi: 10.1186/ar3256.
  45. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992; 326(25):1654-60. doi: 10.1056/nejm199206183262502.